-

Webinar Discussing How Lyme Disease Affects Children to Be Held Aug. 27 and Hosted by Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--Summer is Lyme disease season; and while no age group is immune from potential infection, the disproportionate incidents in children is a stark reality that needs addressing. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric patient population will be held on Thursday, Aug. 27.

The free webinar is part of an ongoing series hosted by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

Conducting the webinar will be Robert A. Dracker, M.D., medical director at Summerwood Pediatrics and Infusacare Medical Services in Liverpool, New York. Dr. Dracker currently serves as chair of the heart, lung and cancer committee for the Medical Society of New York State and is a board member of the Office of Professional Conduct for the New York State Department of Health. Since 2014 he has been a member of the Pediatric Advisory Committee of the FDA and served as chairman of the committee from 2018-2019.

The Aug. 27 webinar will discuss how Lyme disease presents in children (often flu-like symptoms including fever, chills, malaise and headache), how it progresses and tick-exposure management. Also discussed will be how to test for Lyme disease, including the innovative Sofia 2 Lyme FIA test. This in-office test provides a patient as well as physicians with indicative results within minutes as opposed to days, which has historically been the norm.

“Disease presentation in children is extremely variable and may present with confounding symptoms, suggestive of various other infectious or rheumatologic illnesses,” said Dr. Dracker. “Confounding the challenge is that most patients and their parents never remember or notice a tick bite, since most are nymph related. But the reality is that, for the most part, children are more engaged on a regular basis than are adults in outside activities that could expose them to tick bites, which is why being on guard and testing for Lyme disease is so important.”

Among those expected to attend the webinar are pediatricians, representatives of physician office laboratories, urgent care centers and any other allied health professionals or health care researchers interested in hearing the latest regarding the prevalence of Lyme disease in children. The free, Aug. 27 webinar will take place from noon-1 p.m. (EDT). To register, visit quidel.com/webinars.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the health care system. Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions including not only Lyme disease but, among others, COVID-19, influenza, respiratory syncytial virus, strep A, herpes, pregnancy, thyroid disease, fecal occult blood, myocardial infarction, acute coronary syndrome, heart failure, disseminated intravascular coagulation, pulmonary edema, deep vein thrombosis and drug abuse. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of health care in physicians’ offices and hospital and reference laboratories. For more information about Quidel, visit quidel.com.

Contacts

Jim Yeager
424.644.0225 (office)
818.264.6812 (mobile)
jim@breakwhitelight.com

Quidel Corporation


Release Summary
Quidel Corporation is hosting an important webinar focused on how Lyme disease affects the pediatric patient population on Thursday, Aug. 27.
Release Versions

Contacts

Jim Yeager
424.644.0225 (office)
818.264.6812 (mobile)
jim@breakwhitelight.com

More News From Quidel Corporation

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for success...

Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The webinar, available at https://edu...

Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness

SAN DIEGO--(BUSINESS WIRE)--With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rap...
Back to Newsroom